Literature DB >> 1689365

Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor.

T Espevik1, M Brockhaus, H Loetscher, U Nonstad, R Shalaby.   

Abstract

Three different antibodies against a human TNF receptor (htr-1, htr-5, and htr-9) have been examined for their binding pattern to U937 cells and ability to mimic TNF-alpha activity in U937 cells, Fs4 fibroblasts, and human endothelial cells. Flow cytometric analysis revealed that htr-5 and htr-9 bound specifically to a TNF receptor on U937 cells that could be blocked by pretreatment with rTNF-alpha. Pretreatment of U937 cells with rTNF-beta blocked the binding of htr-9, but to a lesser extent htr-5 binding. Pretreatment with htr-5 inhibited the binding of htr-9 to U937 cells while pretreatment with htr-9 did not inhibit htr-5 binding. These results indicate that htr-5 and htr-9 recognize distinct but overlapping epitopes of a human TNF receptor on U937 cells and that htr-5 may be close to a TNF-alpha-specific domain of the binding site. Pretreatment with htr-5 or htr-9 only minimally reduced binding of BrTNF-alpha to U937 cells; however, these antibodies were much more effective in inhibiting BrTNF-alpha binding to HL-60 cells. Furthermore, it was found that htr-1 and htr-9, but not htr-5, had TNF-alpha activity on U937 cells, Fs4 fibroblasts, and endothelial cells and that the TNF-alpha activity induced by htr-9 was completely inhibited by htr-5. However, the cytotoxic activity of TNF-alpha was only partially inhibited by htr-5 on U937 cells while htr-5 had no effect on TNF-alpha activity on Fs4 cells. The data suggest that a common epitope is involved in inducing TNF-alpha activity in three different cell systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689365      PMCID: PMC2187730          DOI: 10.1084/jem.171.2.415

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

2.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

Authors:  J R Gamble; J M Harlan; S J Klebanoff; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Factors influencing endothelial cell proliferation in vitro.

Authors:  R T Wall; L A Harker; L J Quadracci; G E Striker
Journal:  J Cell Physiol       Date:  1978-08       Impact factor: 6.384

4.  Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin.

Authors:  H C Kelker; J D Oppenheim; D Stone-Wolff; D Henriksen-DeStefano; B B Aggarwal; H C Stevenson; J Vilcek
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

5.  Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Authors:  M R Shalaby; B B Aggarwal; E Rinderknecht; L P Svedersky; B S Finkle; M A Palladino
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

6.  Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.

Authors:  P W Gray; B B Aggarwal; C V Benton; T S Bringman; W J Henzel; J A Jarrett; D W Leung; B Moffat; P Ng; L P Svedersky
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Effect of tumor necrosis factor alpha on mitogen-activated human B cells.

Authors:  J H Kehrl; A Miller; A S Fauci
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

8.  Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.

Authors:  J Vilcek; V J Palombella; D Henriksen-DeStefano; C Swenson; R Feinman; M Hirai; M Tsujimoto
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

9.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  43 in total

1.  Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis.

Authors:  B Heilig; M Wermann; H Gallati; M Brockhaus; B Berke; O Egen; A Pezzutto; W Hunstein
Journal:  Clin Investig       Date:  1992-01

2.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

3.  Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis.

Authors:  A S Gukovskaya; I Gukovsky; V Zaninovic; M Song; D Sandoval; S Gukovsky; S J Pandol
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor.

Authors:  G Herbein; L J Montaner; S Gordon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Signal transduction by tumor necrosis factor mediated by JNK protein kinases.

Authors:  H K Sluss; T Barrett; B Dérijard; R J Davis
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

6.  Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.

Authors:  M Lewis; L A Tartaglia; A Lee; G L Bennett; G C Rice; G H Wong; E Y Chen; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

7.  Studies on the expression of the TNF alpha receptors (p55 and p75) and their relative contributions to prostanoid production and glycolytic rate by rheumatoid synovial fibroblasts in vitro.

Authors:  D J Taylor
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

8.  Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.

Authors:  M Kristensen; C Q Chu; D J Eedy; M Feldmann; F M Brennan; S M Breathnach
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

9.  Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes.

Authors:  J Garrigues; U Garrigues; I Hellström; K E Hellström
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

10.  Butylated hydroxyanisole inhibits tumor necrosis factor-induced cytotoxicity and arachidonic acid release.

Authors:  O L Brekke; T Espevik; K S Bjerve
Journal:  Lipids       Date:  1994-02       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.